Scaling up n-of-1 trials; and more
Spectrum (The Transmitter)
A new study outlines a method to scale up genetic therapies tested in n-of-1 trials by using gene-specific haplotyping to identify compatible patients for antisense oligonucleotides targeting SCN2A variants. The approach aims to prequalify a set of oligonucleotides that address the most common causal mutations, potentially expanding access to these therapies. This strategy could help move personalized genetic treatments from individual cases to broader applications.
Read at Spectrum (The Transmitter)
All articles from 17 November 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.
Get this news by email
Daily or as a weekly roundup in your inbox. You confirm your address first; every email has an unsubscribe link. For another topic or language, use the subscribe page.